Sawyers, Charles L.

Publications

Sort by

Co-Author Network

selected publications

Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 2024 Academic Article GET IT
Times cited: 5
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. Cancer cell. 2024 Letter GET IT
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. NPJ precision oncology. 2024 Academic Article GET IT
Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies. 2024 GET IT
The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. 2024 GET IT
ERG activates a stem-like proliferation-differentiation program in prostate epithelial cells with mixed basal-luminal identity. 2024 GET IT
Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer. 2024 GET IT
Strategies to decrease inequalities in cancer therapeutics, care and prevention. Molecular oncology. 2023 Academic Article GET IT
ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES. 2023 GET IT
Addressing racial and ethnic disparities in AACR project GENIE. NPJ precision oncology. 2023 Letter GET IT
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Science translational medicine. 2023 Academic Article GET IT
Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1. Molecular cell. 2023 Academic Article GET IT
Times cited: 10
Macrophages promote anti-androgen resistance in prostate cancer bone disease. The Journal of experimental medicine. 2023 Academic Article GET IT
Times cited: 34
An immunocompetent rectal cancer model to study radiation therapy. Cell reports methods. 2022 Academic Article GET IT
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science (New York, N.Y.). 2022 Academic Article GET IT
Times cited: 130
Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance. JCO precision oncology. 2022 Academic Article GET IT
Author Correction: Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes. 2022 GET IT
Allosteric interactions prime androgen receptor dimerization and activation. Molecular cell. 2022 Academic Article GET IT
Times cited: 30
Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer research. 2022 Academic Article GET IT
Times cited: 30
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nature communications. 2021 Academic Article GET IT
Times cited: 16
Rapid interrogation of cancer cell of origin through CRISPR editing. Proceedings of the National Academy of Sciences of the United States of America. 2021 Academic Article GET IT
Times cited: 12
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO precision oncology. 2020 Academic Article GET IT
Times cited: 37
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer cell. 2020 Academic Article GET IT
Times cited: 70
Linked Entity Attribute Pair (LEAP): A Harmonization Framework for Data Pooling. JCO clinical cancer informatics. 2020 Academic Article GET IT
Times cited: 2
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer cell. 2020 Academic Article GET IT
Times cited: 158
Publisher Correction: Lineage plasticity in cancer: a shared pathway of therapeutic resistance. 2020 GET IT
Times cited: 1
Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis. Cancer discovery. 2020 Academic Article GET IT
Times cited: 39
Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science (New York, N.Y.). 2020 Academic Article GET IT
Times cited: 162
Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG. Proceedings of the National Academy of Sciences of the United States of America. 2020 Academic Article GET IT
Times cited: 35
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer cell. 2020 Academic Article GET IT
Times cited: 100
Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nature reviews. Clinical oncology. 2020 Review GET IT
Times cited: 290
Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2. Cancer research. 2020 Academic Article GET IT
Times cited: 11
Characteristics and Outcome of AKT1 ^E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer discovery. 2020 Academic Article GET IT
Times cited: 42
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses. Journal of visualized experiments : JoVE. 2019 Academic Article GET IT
Times cited: 14
A rectal cancer organoid platform to study individual responses to chemoradiation. Nature medicine. 2019 Academic Article GET IT
Times cited: 347
Herceptin: A First Assault on Oncogenes that Launched a Revolution. Cell. 2019 Academic Article GET IT
Times cited: 21
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019 Academic Article GET IT
Times cited: 165
Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 833
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA oncology. 2019 Academic Article GET IT
Times cited: 481
Disruption of MAGI2-RapGEF2-Rap1 signaling contributes to podocyte dysfunction in congenital nephrotic syndrome caused by mutations in MAGI2. Kidney international. 2019 Academic Article GET IT
Times cited: 14
Strategies to Identify and Target Cells of Origin in Prostate Cancer. Journal of the National Cancer Institute. 2019 Comment GET IT
Times cited: 3
GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance. eLife. 2019 Academic Article GET IT
Times cited: 16
SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 74
American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives. JCO clinical cancer informatics. 2018 Review GET IT
Times cited: 27
Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. eLife. 2018 Academic Article GET IT
Times cited: 196
Patient derived organoids to model rare prostate cancer phenotypes. Nature communications. 2018 Academic Article GET IT
Times cited: 260
Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cellular and molecular gastroenterology and hepatology. 2018 Academic Article GET IT
Times cited: 47
The long tail of oncogenic drivers in prostate cancer. Nature genetics. 2018 Academic Article GET IT
Times cited: 580
Challenges in validating candidate therapeutic targets in cancer. eLife. 2018 Academic Article GET IT
Times cited: 22
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA oncology. 2018 Academic Article GET IT
Times cited: 90
Targeting DNA Repair in Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Comment GET IT
Times cited: 4
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European urology. 2017 Review GET IT
Times cited: 104
Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nature communications. 2017 Academic Article GET IT
Times cited: 19
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. eLife. 2017 Academic Article GET IT
Times cited: 136
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Academic Article GET IT
Times cited: 371
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. 2017 Academic Article GET IT
Times cited: 62
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 417
Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. The New England journal of medicine. 2017 Academic Article GET IT
Times cited: 32
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 20
Dorcas Cummings Lecture. Cold Spring Harbor symposia on quantitative biology. 2017 Conference Paper GET IT
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science (New York, N.Y.). 2017 Academic Article GET IT
Times cited: 756
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (New York, N.Y.). 2017 Academic Article GET IT
Times cited: 744
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell reports. 2016 Academic Article GET IT
Times cited: 86
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PloS one. 2016 Academic Article GET IT
Times cited: 20
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 1251
Organoid culture systems for prostate epithelial and cancer tissue. Nature protocols. 2016 Academic Article GET IT
Times cited: 466
Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Molecular pharmaceutics. 2016 Academic Article GET IT
Times cited: 12
Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors. Cell reports. 2015 Academic Article GET IT
Times cited: 49
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature reviews. Cancer. 2015 Information Resource GET IT
Times cited: 1041
All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. Cancer discovery. 2015 Letter GET IT
Times cited: 30
Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer research. 2015 Academic Article GET IT
Times cited: 109
Identification of an oncogenic RAB protein. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 104
Integrative clinical genomics of advanced prostate cancer. Cell. 2015 Academic Article GET IT
Times cited: 2536
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer cell. 2014 Academic Article GET IT
Times cited: 203
Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Molecular cancer therapeutics. 2014 Academic Article GET IT
Times cited: 30
MAGI-2 scaffold protein is critical for kidney barrier function. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 35
Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 2014 Academic Article GET IT
Times cited: 576
Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Academic Article GET IT
Times cited: 1164
The imperative to invest in science has never been greater. The Journal of clinical investigation. 2014 Article GET IT
Times cited: 4
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes & development. 2014 Academic Article GET IT
Times cited: 161
Copy number alteration burden predicts prostate cancer relapse. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 272
Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Molecular imaging. 2014 Academic Article GET IT
Times cited: 8
SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia (New York, N.Y.). 2014 Academic Article GET IT
Times cited: 123
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013 Academic Article GET IT
Times cited: 779
AACR Cancer Progress Report 2013. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 51
Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer discovery. 2013 Academic Article GET IT
Times cited: 431
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature medicine. 2013 Academic Article GET IT
Times cited: 237
Perspective: combined forces. Nature. 2013 Academic Article GET IT
Times cited: 9
Developing standards for breakthrough therapy designation in oncology. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 25
Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife. 2013 Academic Article GET IT
Times cited: 336
β4 Integrin signaling induces expansion of prostate tumor progenitors. The Journal of clinical investigation. 2013 Academic Article GET IT
Times cited: 80
Imaging tumor burden in the brain with 89Zr-transferrin. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012 Academic Article GET IT
Times cited: 37
Annotating MYC status with 89Zr-transferrin imaging. Nature medicine. 2012 Academic Article GET IT
Times cited: 78
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer research. 2012 Academic Article GET IT
Times cited: 175
AACR Cancer Progress Report 2012. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 16
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 81
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature genetics. 2012 Academic Article GET IT
Times cited: 1018
Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PloS one. 2012 Academic Article GET IT
Times cited: 24
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer discovery. 2012 Academic Article GET IT
Times cited: 68
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer research. 2012 Academic Article GET IT
Times cited: 588
The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs. Transactions of the American Clinical and Climatological Association. 2012 Conference Paper GET IT
Times cited: 9
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PloS one. 2011 Academic Article GET IT
Times cited: 43
Visualization of the interstitial cells of cajal (ICC) network in mice. Journal of visualized experiments : JoVE. 2011 Academic Article GET IT
Times cited: 13
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. European urology. 2011 Academic Article GET IT
Times cited: 175
Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer genetics. 2011 Academic Article GET IT
Times cited: 21
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Science translational medicine. 2011 Academic Article GET IT
Times cited: 53
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 263
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer cell. 2011 Academic Article GET IT
Times cited: 995
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011 Academic Article GET IT
Times cited: 357
MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PloS one. 2011 Academic Article GET IT
Times cited: 72
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 266
Drug discovery: How melanomas bypass new therapy. Nature. 2010 Article GET IT
Times cited: 40
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010 Academic Article GET IT
Times cited: 268
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 548
Integrative genomic profiling of human prostate cancer. Cancer cell. 2010 Academic Article GET IT
Times cited: 3017
Even better kinase inhibitors for chronic myeloid leukemia. The New England journal of medicine. 2010 Editorial Article GET IT
Times cited: 30
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model. The Prostate. 2010 Academic Article GET IT
Times cited: 29
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (London, England). 2010 Academic Article GET IT
Times cited: 969
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). Journal of medicinal chemistry. 2010 Academic Article GET IT
Times cited: 245
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leukemia research. 2009 Academic Article GET IT
Times cited: 6
Lessons learned from the development of kinase inhibitors. Clinical advances in hematology & oncology : H&O. 2009 Academic Article GET IT
Times cited: 3
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer cell. 2009 Academic Article GET IT
Times cited: 119
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, N.Y.). 2009 Academic Article GET IT
Times cited: 1914
Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. The Prostate. 2009 Academic Article GET IT
Times cited: 20
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer research. 2009 Academic Article GET IT
Times cited: 160
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer cell. 2008 Academic Article GET IT
Times cited: 195
Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address. The Journal of clinical investigation. 2008 Conference Paper GET IT
Times cited: 11
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer research. 2008 Academic Article GET IT
Times cited: 166
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer cell. 2008 Academic Article GET IT
Times cited: 151
Targeting the androgen receptor pathway in prostate cancer. Current opinion in pharmacology. 2008 Information Resource GET IT
Times cited: 346
The cancer biomarker problem. Nature. 2008 Information Resource GET IT
Times cited: 672
Something lost--something gained: the ASCI begins its second century. The Journal of clinical investigation. 2008 Article GET IT
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Molecular cancer therapeutics. 2008 Academic Article GET IT
Times cited: 21
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine. 2008 Academic Article GET IT
Times cited: 495
Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer. Cancer research. 2007 Conference Paper GET IT
Times cited: 2
Cancer: mixing cocktails. Nature. 2007 Article GET IT
Times cited: 55
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2007 Academic Article GET IT
Times cited: 193
Where lies the blame for resistance--tumor or host?. Nature medicine. 2007 Article GET IT
Times cited: 10
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. The Journal of clinical investigation. 2007 Academic Article GET IT
Times cited: 340
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer research. 2007 Academic Article GET IT
Times cited: 131
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer cell. 2007 Academic Article GET IT
Times cited: 192
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia. 2007 Academic Article GET IT
Times cited: 25
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 176
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 124
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS medicine. 2006 Academic Article GET IT
Times cited: 293
Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer research. 2006 Academic Article GET IT
Times cited: 22
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer research. 2006 Academic Article GET IT
Times cited: 203
Will kinase inhibitors have a dark side?. The New England journal of medicine. 2006 Academic Article GET IT
Times cited: 34
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England journal of medicine. 2006 Academic Article GET IT
Times cited: 1396
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 70
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2006 Academic Article GET IT
Times cited: 494
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer research. 2006 Academic Article GET IT
Times cited: 236
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer research. 2005 Academic Article GET IT
Times cited: 96
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature medicine. 2005 Academic Article GET IT
Times cited: 513
Amplification and overexpression of prosaposin in prostate cancer. Genes, chromosomes & cancer. 2005 Academic Article GET IT
Times cited: 43
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2005 Academic Article GET IT
Times cited: 69
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Information Resource GET IT
Times cited: 820
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England journal of medicine. 2005 Academic Article GET IT
Times cited: 1178
Update on the use of imatinib mesylate. Clinical advances in hematology & oncology : H&O. 2005 Academic Article GET IT
Times cited: 3
Calculated resistance in cancer. Nature medicine. 2005 Article GET IT
Times cited: 24
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America. 2005 Academic Article GET IT
Times cited: 509
Dynamics of chronic myeloid leukaemia. Nature. 2005 Academic Article GET IT
Times cited: 645
Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature. 2005 Academic Article GET IT
Times cited: 251
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proceedings of the National Academy of Sciences of the United States of America. 2005 Academic Article GET IT
Times cited: 275
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2005 Academic Article GET IT
Times cited: 96
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 56
Targeted cancer therapy. Nature. 2004 Information Resource GET IT
Times cited: 824
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer cell. 2004 Academic Article GET IT
Times cited: 274
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2004 Academic Article GET IT
Times cited: 175
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. The New England journal of medicine. 2004 Academic Article GET IT
Times cited: 1225
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, N.Y.). 2004 Academic Article GET IT
Times cited: 1488
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 401
Molecular determinants of resistance to antiandrogen therapy. Nature medicine. 2003 Academic Article GET IT
Times cited: 1860
Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes & development. 2003 Information Resource GET IT
Times cited: 157
Will mTOR inhibitors make it as cancer drugs?. Cancer cell. 2003 Information Resource GET IT
Times cited: 173
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. The Journal of biological chemistry. 2003 Academic Article GET IT
Times cited: 296
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003 Information Resource GET IT
Times cited: 185
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer cell. 2003 Academic Article GET IT
Times cited: 560
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer research. 2003 Academic Article GET IT
Times cited: 396
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 111
MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts. The Prostate. 2003 Academic Article GET IT
Times cited: 26
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002 Academic Article GET IT
Times cited: 261
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002 Academic Article GET IT
Times cited: 475
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer research. 2002 Academic Article GET IT
Times cited: 81
Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes, chromosomes & cancer. 2002 Academic Article GET IT
Times cited: 39
Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Editorial Article GET IT
The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics. 2002 Information Resource GET IT
Times cited: 22
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. European journal of nuclear medicine and molecular imaging. 2002 Academic Article GET IT
Times cited: 50
Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nature genetics. 2002 Academic Article GET IT
Times cited: 139
Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia. 2002 Academic Article GET IT
Times cited: 50
Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene. 2002 Academic Article GET IT
Times cited: 151
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of Sciences of the United States of America. 2002 Academic Article GET IT
Times cited: 244
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002 Academic Article GET IT
Times cited: 57
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood. 2002 Academic Article GET IT
Times cited: 94
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Current opinion in hematology. 2002 Information Resource GET IT
Times cited: 101
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer cell. 2002 Information Resource GET IT
Times cited: 111
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 Academic Article GET IT
Times cited: 1031
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002 Academic Article GET IT
Times cited: 222
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Molecular and cellular biology. 2002 Academic Article GET IT
Times cited: 184
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002 Academic Article GET IT
Times cited: 941
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. The New England journal of medicine. 2002 Academic Article GET IT
Times cited: 1766
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer cell. 2002 Information Resource GET IT
Times cited: 41
Rational therapeutic intervention in cancer: kinases as drug targets. Current opinion in genetics & development. 2002 Information Resource GET IT
Times cited: 112
Research on resistance to cancer drug Gleevec. Science (New York, N.Y.). 2001 Article GET IT
Times cited: 38
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer research. 2001 Academic Article GET IT
Times cited: 201
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 570
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 923
Defining a common region of deletion at 13q21 in human cancers. Genes, chromosomes & cancer. 2001 Academic Article GET IT
Times cited: 30
Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia. Seminars in hematology. 2001 Editorial Article GET IT
Times cited: 2
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Seminars in hematology. 2001 Information Resource GET IT
Times cited: 23
Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene. 2001 Academic Article GET IT
Times cited: 81
Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia. 2001 Academic Article GET IT
Times cited: 12
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. The New England journal of medicine. 2001 Academic Article GET IT
Times cited: 2366
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England journal of medicine. 2001 Academic Article GET IT
Times cited: 4266
Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer. Current opinion in investigational drugs (London, England : 2000). 2001 Information Resource GET IT
Times cited: 6
Chronic myelogenous leukemia. Hematology. American Society of Hematology. Education Program. 2001 Information Resource GET IT
Times cited: 98
Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer research. 2001 Academic Article GET IT
Times cited: 35
c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency. Proceedings of the National Academy of Sciences of the United States of America. 2000 Academic Article GET IT
Times cited: 27
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proceedings of the National Academy of Sciences of the United States of America. 2000 Academic Article GET IT
Times cited: 348
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Molecular and cellular biology. 2000 Academic Article GET IT
Times cited: 168
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer research. 1999 Academic Article GET IT
Times cited: 251
Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. The Journal of biological chemistry. 1999 Academic Article GET IT
Times cited: 129
Chronic myeloid leukemia. The New England journal of medicine. 1999 Article GET IT
Times cited: 8
C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood. 1999 Academic Article GET IT
Times cited: 154
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Molecular and cellular biology. 1999 Academic Article GET IT
Times cited: 183
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission. Leukemia & lymphoma. 1999 Academic Article GET IT
Times cited: 8
Chronic myeloid leukemia. The New England journal of medicine. 1999 Information Resource GET IT
Times cited: 1225
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature medicine. 1999 Academic Article GET IT
Times cited: 822
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proceedings of the National Academy of Sciences of the United States of America. 1998 Academic Article GET IT
Times cited: 603
Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Molecular and cellular biology. 1998 Academic Article GET IT
Times cited: 63
Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood. 1998 Academic Article GET IT
Times cited: 92
Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. Journal of the National Cancer Institute. 1998 Academic Article GET IT
Times cited: 21
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proceedings of the National Academy of Sciences of the United States of America. 1998 Academic Article GET IT
Times cited: 571
Functional role for the c-Abl tyrosine kinase in meiosis I. Oncogene. 1998 Academic Article GET IT
Times cited: 41
Oncogene Expression and Cellular Radiation Resistance: A Modulatory Role for c-myc. Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology. 1998 Academic Article GET IT
Mechanistic concepts in androgen-dependence of prostate cancer. Cancer metastasis reviews. 1998 Information Resource GET IT
Times cited: 56
Signal transduction by wild-type and leukemogenic Abl proteins. Biochimica et biophysica acta. 1997 Information Resource GET IT
Times cited: 102
Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission. Leukemia. 1997 Academic Article GET IT
Times cited: 20
A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (New York, N.Y.). 1997 Academic Article GET IT
Times cited: 619
New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica. 1997 Information Resource GET IT
Times cited: 45
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature medicine. 1997 Academic Article GET IT
Times cited: 323
Molecular genetics of acute leukaemia. Lancet (London, England). 1997 Information Resource GET IT
Times cited: 34
Signal transduction-based strategies for the treatment of chronic myelogenous leukemia. Molecular medicine today. 1996 Information Resource GET IT
Times cited: 8
Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53. The Journal of biological chemistry. 1996 Academic Article GET IT
Times cited: 63
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. The Journal of biological chemistry. 1996 Academic Article GET IT
Times cited: 115
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996 Academic Article GET IT
Times cited: 394
Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature. 1996 Academic Article GET IT
Times cited: 207
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proceedings of the National Academy of Sciences of the United States of America. 1995 Academic Article GET IT
Times cited: 384
p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase. Oncogene. 1995 Academic Article GET IT
Times cited: 134
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. The Journal of experimental medicine. 1995 Academic Article GET IT
Times cited: 253
Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination. Proceedings of the National Academy of Sciences of the United States of America. 1994 Academic Article GET IT
Times cited: 13
In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer. Cancer. 1994 Academic Article GET IT
Times cited: 40
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice. International journal of cancer. 1994 Academic Article GET IT
Times cited: 1
Differential complementation of Bcr-Abl point mutants with c-Myc. Science (New York, N.Y.). 1994 Academic Article GET IT
Times cited: 181
The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell. 1994 Academic Article GET IT
Times cited: 242
Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992 Academic Article GET IT
Times cited: 338
Propagation of human blastic myeloid leukemias in the SCID mouse. Blood. 1992 Academic Article GET IT
Times cited: 84
The bcr-abl gene in chronic myelogenous leukaemia. Cancer surveys. 1992 Information Resource GET IT
Times cited: 47
Leukemia and the disruption of normal hematopoiesis. Cell. 1991 Information Resource GET IT
Times cited: 304
Significance of residual leukaemia transcripts after bone marrow transplant for CML. Lancet (London, England). 1990 Article GET IT
Times cited: 13
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America. 1990 Academic Article GET IT
Times cited: 126
A model for predicting nephrotoxicity in patients treated with aminoglycosides. The Journal of infectious diseases. 1986 Academic Article GET IT
Times cited: 91

more ...

less ...

Background

education and training

M.D., The Johns Hopkins University School of Medicine 1985
B.A., Princeton University 1981

Contact

full name

Charles L. Sawyers

primary email

sawyersc@mskcc.org

VIVO Weill Cornell Medical College

Charles L. Sawyers Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email